Private Advisor Group LLC Has $225,000 Stock Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Private Advisor Group LLC decreased its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 48.3% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 26,992 shares of the company’s stock after selling 25,200 shares during the quarter. Private Advisor Group LLC’s holdings in Amneal Pharmaceuticals were worth $225,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Rothschild Investment LLC acquired a new position in Amneal Pharmaceuticals in the 2nd quarter worth about $26,000. DekaBank Deutsche Girozentrale acquired a new position in Amneal Pharmaceuticals in the second quarter worth approximately $42,000. Atlanta Consulting Group Advisors LLC bought a new position in Amneal Pharmaceuticals during the first quarter valued at approximately $61,000. nVerses Capital LLC acquired a new stake in Amneal Pharmaceuticals in the second quarter valued at approximately $62,000. Finally, Bayesian Capital Management LP bought a new stake in Amneal Pharmaceuticals in the first quarter worth approximately $65,000. 31.82% of the stock is owned by institutional investors and hedge funds.

Amneal Pharmaceuticals Stock Up 1.3 %

Shares of NASDAQ:AMRX opened at $8.61 on Friday. The business has a 50 day moving average price of $8.53 and a 200 day moving average price of $7.51. The company has a market cap of $2.67 billion, a price-to-earnings ratio of -13.89 and a beta of 1.17. Amneal Pharmaceuticals, Inc. has a twelve month low of $3.96 and a twelve month high of $8.95.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings data on Friday, August 9th. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.04. Amneal Pharmaceuticals had a positive return on equity of 1,235.03% and a negative net margin of 6.72%. The company had revenue of $701.78 million during the quarter, compared to analysts’ expectations of $657.43 million. Analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.52 EPS for the current year.

Analyst Ratings Changes

AMRX has been the topic of a number of recent research reports. JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price target on the stock in a report on Friday, September 6th. Truist Financial increased their target price on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Wednesday, October 2nd. Finally, Barclays upped their price target on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 13th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $9.40.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.